Company / Capital Expenditures
ANI Pharmaceuticals, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$13.8M
FY2025
5-year range
$2.6M / $16.2M
FY2021-FY2025
Trend
-14.8%
vs FY2024
Sector context
#50 of 194
Health Care
What the data says
At $14M, ANI Pharmaceuticals, Inc.'s capital expenditures ranks #50 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $3M in FY2021 to $16M in FY2024.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +17.7%.
Improved from $9M to $14M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +15.9%
- 5-Year CAGR
- +17.7%
- 10-Year CAGR
- -
Sector benchmark
#50 of 194 in Health CareTop 26% of 194This company $13.8M Sector average $117.5M
▼
-88.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.7%, indicating consistent growth.
- In FY2025, capital expenditures decreased 14.8% year-over-year.
- Ranks #50 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.8M | -14.8% |
| FY2024 | $16.2M | +83.1% |
| FY2023 | $8.9M | -0.1% |
| FY2022 | $8.9M | +247.1% |
| FY2021 | $2.6M | -58.3% |
| FY2020 | $6.1M | -7.5% |
| FY2019 | $6.6M | +15.5% |
| FY2018 | $5.7M | -44.6% |
| FY2017 | $10.4M | +127.1% |
| FY2016 | $4.6M | +2290.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026